Cardiff Oncology price target raised to $10 from $7 at Piper Sandler

Piper Sandler raised the firm’s price target on Cardiff Oncology (CRDF) to $10 from $7 and keeps an Overweight rating on the shares. The company reported initial data from its ongoing randomized Phase II trial of onvansertib in RAS-mutated mutated metastatic colorectal cancer and the early randomized dataset seems to clearly support the hypothesis that onvansertib on top of chemotherapy provides meaningful clinical benefit, the analyst tells investors in a research note. Piper sees the data as meaningfully derisking.”